Autoantibodies to BIRC5 and MYC were measured in cervical cancer patients and a control group.
There was a significant difference in circulating levels of these autoantibodies in the patient and control groups.
ROC analysis suggests that anti-BIRC5 IgG has a higher sensitivity than anti-MYC IgG.
Anti-BIRC5 IgG could serve as a biomarker for the early diagnosis of cervical cancer.